SCHEMBL2645855

SCHEMBL2645855

O=C(O)C(=CCC1CCCC1)c1ccc(F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
CES2 O00748 2/20 0.41
CES1 P23141 2/20 0.41
SSTR3 P32745 2/20 0.37
PLA2G7 Q13093 1/20 0.36
HSD11B1 P28845 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
GAA P10253 1/20 0.34
USP30 Q70CQ3 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2645851 1.00 TAS1R3 (0.42) TAS1R3TAS1R1TAS1R2CES2CES1
SCHEMBL2645960 0.84 TAS1R3 (0.44) TAS1R3TAS1R1TAS1R2CES2CES1
SCHEMBL2645955 0.84 TAS1R3 (0.44) TAS1R3TAS1R1TAS1R2CES2CES1
SCHEMBL2645437 0.77 TAS1R3 (0.44) TAS1R3TAS1R1TAS1R2CES2CES1
SCHEMBL2645435 0.77 TAS1R3 (0.44) TAS1R3TAS1R1TAS1R2CES2CES1
SCHEMBL2645401 0.76 EPHX2 (0.49) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL2645406 0.76 EPHX2 (0.49) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL2336194 0.76 CES2 (0.48) CES2CES1PLA2G7RAB9AMEN1
SCHEMBL2336184 0.76 CES2 (0.48) CES2CES1PLA2G7RAB9AMEN1
SCHEMBL2645319 0.74 AKR1C3 (0.54) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242397-B1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
EP-1242397-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-09-25 EP disclosed
US-6353111-B1 WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A HOFFMANN-LA ROCHE INC. 2002-03-05 US disclosed
WO-2001044216-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-06-21 WO disclosed